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The 6th International Conference of
HPV, Polyomavirus, and UV Radiation
in Skin Cancer was held from 18 to 20
October 2012 in Berlin, Germany. In
total, 150 scientists and physicians from
Europe, the United States, China,
Australia, and New Zealand (including
32 invited experts and speakers) partici-
pated in this congress, which was run
under the auspices of the European Skin
Cancer Foundation. The necessity for
this specific meeting is reflected by the
strong increase in the knowledge and
scientific interest in the role of onco-
genic viruses and nonmelanoma skin
cancer. A particular focus of this skin
cancer conference was laid on UV radia-
tion (DNA damage), cutaneous human
papillomavirus (HPV) types, and poly-
omaviruses. Novel trends in basic
research, translational research, epide-
miology, and therapy were reported by
international experts and 15 selected
abstracts. In addition, guided poster walks
were conducted to stimulate scientific
discussions and to exchange ideas.
In general, 20% of all cancers are
known to be causally induced by onco-
genic viruses and it is very likely that this
number will increase in the future. In the
last 3 years, more than 100 original
research publications about cutaneous
HPV types were published, indicating
the increase of knowledge in this
specific research field. In large epide-
miological studies, an increased risk
of cutaneous HPV and cutaneous squa-
mous cell carcinoma (SCC) was shown
in the general population and immuno-
suppressed organ transplant recipients
(OTRs). John Doorbar (London, UK)
reported about the life cycle of genital
(alpha-PV) and cutaneous HPV (beta-
and gamma-PV). The life cycle and
transmission of cutaneous HPV differs
from genital types. Cutaneous HPV
complete their life cycle in the hair
follicles and the genome is not sustained
in rapidly dividing keratinocytes, leading
to a lack of viral genome itself, which is
consistent with a low viral load in
human dysplastic cells of actinic kera-
tosis and SCC. Michel Favre (Paris,
France) reported the up-to-date knowl-
edge about EVER proteins in HPV-
infected skin. Epidermodysplasia verru-
ciformis (EV) patients have an immune
defect and mutations in EVER genes,
which are characterized by an abnormal
susceptibility to cutaneous HPV (beta-
PV), resulting in cutaneous SCC on sun-
exposed sites. EVER2 proteins have a
central role in the immune response of
keratinocytes and the control of NF-kB
and AP-1 signaling pathways, and thus
may regulate cutaneous HPV infections.
In a keynote lecture, Jens-Michael
Schro¨der (Kiel, Germany), a pioneer in
the research of antimicrobial peptides
and innate immune mechanisms of the
skin, reported about the versatile func-
tions of antimicrobial peptides in the
antiviral defense. Overall, virus infection
of various epithelial cells induces either
directly or indirectly (via IFN-b) a spe-
cific set of antimicrobial peptides. Cuta-
neous HPV infection of the skin induces
human b-defensins, hBD-2 and hBD-3,
and genital HPV types in the mucosa,
and two human a-defensins, HNP-1 and
HD-5, mostly in the absence of inflam-
mation. The antiviral mechanisms of
antimicrobial peptides, as exemplified
by using HIV and influenza viruses as
model systems, include effects on the
virions (membrane disruption, glycopro-
tein-binding) on target cell receptors,
and blocking the fusion step of viral
membranes with the endosome, thereby
inhibiting the viral life cycle. Jan N.
Bouwes Bavinck (Leiden, The Nether-
lands) presented, on behalf of the EU
consortium (EPI-HPV-UC-CA group),
epidemiological data about cutaneous
HPV and skin cancer risk in large
cohorts and prospective studies of the
general population and immunosup-
pressed OTRs. There was an association
between cutaneous HPV serology (not
consistent) and HPV infection (not with
a specific type), and a significant asso-
ciation between HPV serology and SCC
in the presence of concordant HPV
infections. In immunosuppressed OTRs,
the presence of cutaneous HPV antibo-
dies and of HPV infections of eyebrow
hairs predicts the risk of SCC develop-
ment. The chance to develop skin can-
cer increased with the number of
cutaneous HPV types. The role of UV
radiation and skin cancer development
and progression was reported by
Petra Boukamp (Heidelberg, Germany).
UVB was considered to be the major
carcinogen by continuous DNA damage,
leading to specific mutations in, e.g.,
p53 and Harvey-ras. Recently, both
UVA and even infrared radiation have
been suggested to act as additional
major contributors inducing reactive
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oxygen species, telomere shortening,
and epigenetic regulation. Both telo-
mere shortening and epigenetic regula-
tion, specifically p16 inhibition, are
known to be important drivers of
genomic instability. Moreover, she
presented evidence of deregulated Wnt
pathway in skin carcinoma by autocrine
stimulation and stromal fibroblast. The
latter supports the important paracrine
stimulatory loop of the microenviron-
ment in promoting tumor progression.
Thomas G. Hofmann (Heidelberg,
Germany), who identified homeodo-
main protein kinase 2 (HIPK2) as a
novel cell fate regulator and p53 kinase,
presented molecular insights into signal-
ing after UV, ionizing radiation, and
chemotherapy-induced DNA damage.
It is well established that deregulation
of cellular DNA damage response
results in genomic instability. A major
function of HIPK2 after DNA damage is
the phosphorylation of p53 at Ser46 in
nuclear bodies, resulting in the activa-
tion of apoptosis. The inhibitor of
cyclin-dependent kinase interacting
with Cyclin A1 (INCA1) was shown to
be a novel regulator of HIPK2 activity
beyond proteasome-dependent degra-
dation. INCA1 directly binds to HIPK2
and inhibits its kinase activity in
unstressed cells. Upon lethal DNA
damage, cells overcome apoptosis inhi-
bition by INCA1 by triggering INCA1
degradation through a phosphorylation-
dependent mechanism. Novel findings
of molecular mechanisms of cutaneous
HPV types were summarized by Alan
Storey (Oxford, UK). The E6 protein of
cutaneous HPV5 binds HERC1 to
target Bak for degradation, promoting
cell survival after UV-induced DNA
damage. In undamaged cells, there is
no interaction of viral E6 with Bak
indicating the specific anti-apoptotic
potential of cutaneous HPV. The role
of viral E6 and E7 oncogenes of cuta-
neous HPV types were addressed by
Massimo Tommasino (Lyon, France).
He reported on the characterization of
cutaneous HPV E6 and E7 biological
properties with in vitro experimental
models. Both oncoproteins of HPV38
and HPV49 induce immortalization of
human primary keratinocytes, which
was associated with inactivation of
pathways controlled by pRb and p53.
Interestingly, cutaneous HPV do not just
induce DNp73a accumulation, which
thus appears to be a more general
virus-mediated mechanism to alter the
p53 transcriptional functions. The onco-
genic potential of cutaneous HPV types
in transgenic mice was reported by
Herbert Pfister (Cologne, Germany).
HPV8 shows carcinogenic activity in
the skin of transgenic mice, and carci-
nogenesis strictly depends on the viral
expression levels of the E6 oncogene. A
delay and reduction of papilloma
growth was observed after knockdown
of E6 by small interfering RNA. Interest-
ingly, an increased tumor development
was also found in HPV8 E2 transgenic
mice. Here a balanced level of viral
oncogene expression is required to
induce skin tumors, which in addition
may tag infected cells for the immune
system of immunized animals. Remark-
ably, the immune system appears to
attack keratinocytes exclusively with
increased E6 protein levels, which are
necessary for the development of papil-
loma. Thus, a preventive vaccine could
be very useful for immunosuppressed
OTRs, which have a high risk to develop
cutaneous SCC. Thomas Iftner (Tu¨bin-
gen, Germany) presented data of a
rabbit animal model for papilloma-
virus-associated skin cancer. Cottontail
rabbit PV (CRPV) infects stem cells in
the hair follicles, and high expression of
the oncogenes E6 and E7 are present in
papilloma and skin carcinoma. Both
viral proteins are sufficient to immorta-
lize rabbit primary keratinocytes.
CRPV E6 binds and inhibits p300, which
has also been shown for HPV38 E6. The
ability to activate AP-1 is important for
the enhancer activity of CRPV and to
induce tumor formation in rabbits. In
addition, the E2 protein of CRPV also
regulates cellular genes, such as MMP9,
suggesting that E2 of cutaneous HPV
and PV types may have an oncogenic
potential, which is not the case for
genital HPV types. Sabrina Vinzo´n (Hei-
delberg, Germany) presented the animal
model Mastomys coucha that is suitable
to study natural PV-induced skin cancer.
These animals are naturally infected
with two known PV types, namely,
MnPV1 and McPV2, the etiological
agents of skin cancer and genital lesions
in this animal model. This model is now
complemented by virus-free animals,
which can be experimentally infected.
In a preclinical study, she showed that
MnPV virus-like particle vaccine pro-
tects against skin tumor formation.
Further vaccination studies will provide
important insight, which are the basis
for the implementation of a cutaneous
HPV vaccine in humans. A study on a
cohort of EV patients with HPV and skin
cancer was presented by Marisa
Gariglio (Novara, Italy). She showed
that cutaneous HPV replication is highly
increased under condition of immuno-
suppression (e.g., EV patients and OTRs)
and maintained in high-grade lesions. In
skin lesions of OTRs, HPV activity was
specifically found on the edge of the
hyperplastic lesions. Replication mech-
anisms of genital and cutaneous HPV
types were reported by Alison A.
McBride (Bethesda, USA). The E2
protein from different HPV types links
the viral genomes to host chromosomes
in complex with the cellular Brd4
protein (a cellular chromatin adapter).
Cutaneous HPV8 E2 binds to the rDNA
loci on mitotic chromosomes. Both HPV
proteins, E1 and E2, can form a complex
with Brd4, and the binding of E2 is
required for the formation of foci. High
levels of viral E1 and E2 induce the
DNA damage response and DNA repair
proteins recruited to foci to amplify
genomes. HPV can replicate outside
the S-phase, independent from cellular
DNA replication. Merilyn H. Hibma
(Dunedin, New Zealand) presented an
interaction of HPV and antigen-present-
ing cells in the skin. HPV causes persis-
tent infections that can spontaneously
regress because of the adaptive immune
response. Langerhans cells (LCs) are
reduced in HPV-infected skin of genital
and wart-associated types, whereas no
reduction was observed in the skin of
non-EV patients infected with cutaneous
HPV types (beta-PV). HPV16 E7 expres-
sion in epidermal keratinocytes is suffi-
cient to regulate both LC density and
phenotype. The interaction of cutaneous
HPV with the immune system was
reported by Sigrun Smola (Homburg/
Saar, Germany). In HPV8-infected skin
lesions of EV patients, LCs were strongly
reduced and the important LC chemoat-
tractant protein, CCL20, was not detect-
able. The potent inducer of the CCL20
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gene CCAAT/enhancer-binding protein
b was identified. Moreover, it was
shown that the CCAAT/enhancer-bind-
ing protein b is a novel target of HPV8
E7. In conclusion, LC migration was
strongly inhibited in HPV8 E7-positive
keratinocytes, indicating that cutaneous
HPV can disrupt the immune barrier.
The role and importance of immuno-
suppressive drugs in the development of
cancer was summarized by Edward K.
Geissler (Regensburg, Germany). Infec-
tions with oncogenic viruses are asso-
ciated with immunosuppressed OTR-
related carcinoma. Immunosuppression
promotes viral infections or reinfections
and malignancy. Cancer could be
reduced by lowering immunosuppres-
sion, and mammalian target of rapamy-
cin inhibitors may boost immune
surveillance and inhibit tumor develop-
ment through multiple mechanisms.
Sylvie Euvrard (Lyon, France) reported
about immunosuppressive strategies for
skin cancer of OTRs. A switch of
immunosuppressive drugs to mamma-
lian target of rapamycin inhibitors seems
a promising strategy to reduce skin
cancers in OTRs. The efficacy was
greatest when the conversion is very
early, but the long-term effect remains
to be examined. The honorary presi-
dent, Lutz Gissmann (Heidelberg, Ger-
many), summarized the current state
of prophylactic vaccine against HPV-
induced tumors. HPV vaccines are
highly immunogenic and effective
because they are administered to
regions where normally HPV is not
present, resulting in a better perfor-
mance than expected. Cutaneous HPV
vaccines can protect, in principle,
against viral skin infections. At present,
it is unknown whether prophylactic
vaccines additionally have a therapeutic
effect. Christopher B. Buck (Bethesda,
USA) reported about the cellular tropism
of Merkel cell polyomavirus (MCV).
Cellular entry differs in polyomaviruses,
e.g., MCV and BKV take different routes
to enter cells in monolayer culture. For
cell entry, both the viruses, HPV and
MCV, use heparin sulfate and a post-
attachment coreceptor. HPV and MCV
appear to be nonlytic and pseudolatent,
at least in monolayer cell cultures. Mice
do not seem to be a useful model to
analyze MCV tropism indicated by
polyomavirus infection experiments
with mice. Serological studies with cuta-
neous HPV and polyomaviruses were
presented by Michael Pawlita (Heidel-
berg, Germany). Antibodies recognizing
cutaneous HPV types in general, but not
exclusively a specific type, are asso-
ciated with SCC both in cross-sectional
and prospective follow-up studies. Most
humans are infected with many cuta-
neous HPV types, and individuals differ
in their ability to control infections and
virus replication. The impact on pathol-
ogy of MCV and Merkel cell carcinoma
(MCC) was summarized by Axel zur
Hausen (Maastricht, The Netherlands).
Approximately, 80% of MCCs are
infected with MCV, which was recently
cloned, and are very likely the etiologi-
cal agent of this cancer. Immunohisto-
chemistry of the viral large T antigen
(LT-Ag) is already used to diagnose
MCC. Moreover, several MCV surrogate
markers (e.g., p16INK4a and TdT) are
used in routine pathology to diagnose
MCC. The role of MCV and other
recently discovered human polyoma-
viruses and nonmelanoma skin cancer
will be examined in the future by
fluorescence in situ hybridization and
other routinely used diagnostic meth-
ods. Novel mechanistic data from trans-
forming properties of MCV were
reported by Denise A. Galloway (Seat-
tle, WA). Currently, of the 10 human
polyomaviruses, only MCV has been
firmly associated with skin cancer.
MCV encodes LT-Ag and small T anti-
gens, which are used to inactivate pRB,
p53, and PP2A proteins by SV40. These
genes from MCV did not significantly
extend the lifespan of human foreskin
keratinocytes and nor gene-transformed
rodent fibroblast. Galloway and collea-
gues identified a novel protein named
ALTO in the LT-Ag region and identified
antibodies to ALTO in MCV VP1-sero-
positive patients. The role of this protein
in transformation and the life cycle of
MCV is currently being studied. The
clinical and functional impact of MCV
and MCC was presented by Ju¨rgen C.
Becker (Graz, Austria). MCC is a highly
aggressive and rare skin cancer with an
increasing incidence, particularly in
immunosuppressed patients. MCV
DNA is often clonally integrated in the
tumor and metastases. Most MCC
express viral LT-Ag and the transformed
phenotype of virus-positive cancer cell
lines depends on the LT-Ag expression,
indicating the etiological role of MCV.
Therapeutic approaches that interfere
with LT-Ag using IFN type I seem to
be promising. Indeed, type I IFNs have a
strong antitumor effect, which is at least
partly due to the modulation of viral
LT-Ag. The discovery and function of
microRNA in polyomaviruses and poly-
oma-like viruses were reported by
Christopher S. Sullivan (Austin, USA).
MicroRNAs are small regulatory RNAs
described from Herpes-, Polyoma-,
Retro-, and other viruses. Diverse poly-
omaviruses produce autoregulatory
microRNAs, e.g., similar SV40 strains
have different host miRNA targetomes.
In conclusion, viral microRNA possibly
has an important role in persistent infec-
tions of some polyomaviruses. Nicole
Fischer (Hamburg, Germany) presented
novel data about transforming properties
of MCV. Previously, they have identified
and characterized a truncated LT-Ag of
the MCV-infected MCC cell line. Trun-
cated LT-Ag is expressed at higher levels
compared with the wild-type LT-Ag; it
does not bind p53 or reduce p53-
induced transcription, but showed a
higher affinity for pRb binding. More-
over, truncated LT-Ag interacts with the
heat shock protein, Hsp90. Fischer and
colleagues provide evidence that in
contrast to SV40, full-length LT-Ag of
MCV does not directly bind p53, but
significantly reduces p53-dependent
transcription.
In conclusion, Denise A. Galloway
(Seattle, USA) has summarized the
highlights of the conference in her con-
cluding remarks.
Cutaneous HPV types and skin
cancer
The most important functional
mechanisms of cutaneous HPV types
are the disruption of UV-induced
DNA damage repair by the E6 protein.
In contrast to genital HPV, cutaneous
types do not bind p53, but indirectly
influence different pathways controlled
by p53. For instance, viral E6 protein
binds HIPK2, prevents both HIPK2/p53
interaction and p53 phosphorylation
at Ser46, resulting in the inhibition
of apoptosis. Moreover, E6 binds the
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proapoptotic protein Bak, followed by
the interaction with Herc1, resulting in
ubiquitination and degradation of Bak.
Transgenic mouse models showed
tumorigenic potential and cooperation
with UV radiation in skin carcinogen-
esis. Cutaneous HPV types do not persist
in dividing cells, replicate rarely, and
are only present in about 1 out of 100
dysplastic cells of cutaneous SCC. The
viral load is the highest in EV patients,
followed by immunosuppressed OTRs,
and lowest in the general population.
Epidemiological studies showed that
cutaneous HPV DNA and antibodies are
frequent in cases and controls.
Furthermore, several studies have
shown increased relative risks of skin
cancer with HPV infections, the number
of types, viral load, and seropositivity.
Not a specific HPV type, but the sus-
ceptibility of multiple types, viral repli-
cation and seroconversion are
associated with an increased risk of
cutaneous SCC.
Polyomaviruses and skin cancer
MCV DNA is present in approxi-
mately 80% of MCCs consistently
shown in several studies, and infections
occur before tumor development. MCC
patients have a higher seroprevalence to
MCV capsid and titer compared with
the healthy population. Antibodies to
MCV LT-Ag were only found in cancer
patients, indicating that the expression
of LT-Ag is induced during carcinogen-
esis. Several studies presented trans-
forming properties of MCV, which was
mainly due to LT-Ag, showing that this
novel polyomavirus is very likely the
etiological agent of MCC.
*The 6th International Conference of HPV,
Polyomavirus, and UV Radiation in Skin Cancer
was held at the Charite´ in Berlin, Germany,
18–20 October 2012 (http://hpv2012.de).
The 7th International Conference of HPV, Polyomavirus, and UV Radiation in Skin Cancer
will be held in Novara, Italy, 9–12 April 2014.
Further information about this upcoming conference is available at
http://hpvpolyomanovara2014.it
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